Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 10/20 | 0.66 |
| ▸ | TFPI | P10646 | 1/20 | 0.66 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.58 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060486 | 0.97 | OPRL1 (0.69) | OPRL1TFPI | |
| Nociceptin SCHEMBL29358223 | 0.91 | OPRL1 (0.79) | OPRL1TFPI | |
| SCHEMBL30629356 | 0.90 | VIPR1 (0.71) | TFPIVIPR1KEAP1VIPR2 | |
| SCHEMBL31719706 | 0.89 | TFPI (0.65) | OPRL1TFPIVIPR1VIPR2 | |
| SCHEMBL30130109 | 0.89 | TFPI (0.64) | OPRL1TFPI | |
| SCHEMBL30436109 | 0.88 | TFPI (0.66) | OPRL1TFPIVIPR1VIPR2 | |
| SCHEMBL29973137 | 0.88 | TFPI (0.71) | OPRL1TFPIVIPR1VIPR2 | |
| Nociceptin-Nh2 SCHEMBL30033176 | 0.88 | OPRL1 (0.79) | OPRL1TFPI | |
| SCHEMBL28918838 | 0.88 | OPRL1 (0.70) | OPRL1TFPI | |
| SCHEMBL30182811 | 0.87 | TFPI (0.63) | OPRL1TFPIVIPR1KEAP1VIPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633628-A1 | REGIMENS AND COMPOSITIONS USEFUL FOR ALLEVIATING PAIN | Adneuris Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2025-05-15 | — | — | US | claimed |
| US-12297227-B2 | Method for extracting target protein from biological sample and method for analyzing target protein | MEDIFORD CORPORATION (JP) | 2025-05-13 | — | — | US | claimed |
| WO-2025085826-A1 | ACTIVATION OF ORL1: A NOVEL THERAPY TO PREVENT HEART FAILURE PROGRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | claimed |
| US-20240252585-A1 | METHODS OF TREATING TRAUMATIC BRAIN INJURY AND RELATED NEUROLOGICAL CONDITIONS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA | 2024-08-01 | — | — | US | claimed |
| WO-2024129782-A1 | REGIMENS AND COMPOSITIONS USEFUL FOR ALLEVIATING PAIN | PARK THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| CN-112730849-B | Application of endogenous orphan enkephalin as serum biomarker for diabetes mellitus combined with asymptomatic myocardial ischemia | 山西医科大学第二医院 | 2023-03-10 | — | — | CN | claimed |
| EP-2981292-B1 | SUPRAMOLECULAR AGGREGATES COMPRISING A MALEIMIDO CORE | UFPEPTIDES S R L (IT) | 2022-11-02 | — | — | EP | claimed |
| EP-3587404-B1 | MICROCRYSTALLINE DIKETOPIPERAZINE COMPOSITIONS, METHODS FOR PREPARATION AND USE THEREOF | MANNKIND CORP (US) | 2022-07-13 | — | — | EP | claimed |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2022-02-17 | — | — | US | claimed |
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | MANNKIND CORPORATION (US) | 2026-05-28 | — | — | US | disclosed |
| WO-2026112154-A1 | MCOPPB HYDROCHLORIDE HYDRATE SOLID FORMS AND THEIR USE IN TREATING PAIN AND OTHER DISORDERS | CENTREXION THERAPEUTICS CORPORATION (US) | 2026-05-28 | — | — | WO | disclosed |
| WO-2026103742-A1 | DEUTERATED FUSED RING COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏恩华药业股份有限公司 | 2026-05-21 | — | — | WO | disclosed |
| EP-4744688-A2 | DRUG DELIVERY DEVICES WITH DRUG-PERMEABLE COMPONENT AND METHODS | Janssen Biotech, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12629385-B2 | Stable AST-3424 injection preparation and preparation method | OBI PHARMA, INC. (TW) | 2026-05-19 | — | — | US | disclosed |
| US-11248035-B1 | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | IMMATICS BIOTECHNOLOGIES GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
| US-20220040461-A1 | MULTI-LUMEN DRUG DELIVERY DEVICES AND METHODS | TARIS BIOMEDICAL LLC | 2022-02-10 | — | — | US | disclosed |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OMEROS CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220023260-A1 | Ready to Use Ketorolac Formulations | RTU PHARMACEUTICALS, LLC | 2022-01-27 | — | — | US | disclosed |
| US-11229625-B2 | Titration of Cebranopadol | PARK THERAPEUTICS, INC. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144877-A1 | HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PKD2, SMCHD1 | OPRL1 2062/4885TFPI 741/4885VIPR1 1073/4885 |
| US-20220023260-A1 | Ready to Use Ketorolac Formulations | KHK, VKORC1, PROKR1 | OPRL1 283/4885TFPI 3978/4885VIPR1 519/4885 |
| US-20220048868-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | OPRL1 2827/4885TFPI 2158/4885VIPR1 1012/4885 |
| US-20250154113-A1 | Microcrystalline Diketopiperazine Compositions and Methods | RRP15, DKK1, SPOP | OPRL1 2827/4885TFPI 2158/4885VIPR1 1012/4885 |
| US-12629385-B2 | Stable AST-3424 injection preparation and preparation method | SLC2A4, SLC2A8, F12 | OPRL1 2359/4885TFPI 169/4885VIPR1 1743/4885 |
| US-11241420-B2 | Compositions and methods for prophylaxis and treatment of addictions | OPRK1, OPRL1, PPARA | OPRL1 2/4885TFPI 4671/4885VIPR1 2486/4885 |
| US-11229625-B2 | Titration of Cebranopadol | CYP26B1, DHCR7, CES1 | OPRL1 18/4885TFPI 4481/4885VIPR1 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.